MODULATION OF TH1/TH2 CYTOKINE EXPRESSION BY RIBAVIRIN3 AND RIBAVIRIN3 ANALOGS IN ACTIVATED T-LYMPHOCYTES

Abstract: Ribavirin3 is administered to a patient in a dosage range which is effective to modulate lymphokine expression in activated T cells. In particular, Ribavirin3 is used to suppress Th2-mediated T cell responses and promote Th1-mediated T cell response. In other aspects of the invention, one or more Ribavirin3 analogs are administered to a patient in a dosage range which is effective to modulate lymphokine expression in activated T cells. The Ribavirin3 analog(s) may be used to suppress or enhance Th1 or Th2-mediated T cell responses.

Description: MODULATION OF TH1/TH2 CYTOKINE EXPRESSION BY RIBAVIRIN® AND RIBAVIRIN® ANALOGS IN ACTIVATED T-LY PHOCYTES FIELD OF THE INVENTION The field of the invention is immunology. 5 BACKGROUND OF THE INVENTION The lymphokines are a group of polypeptides belonging to the family of cytokines. i.e. hormone-like molecules that can affect various cell functions and enable communication between different cells. Recent developments have helped to clarify the role of lymphokines in 1(She immune response. Lymphokine production by helper CD4 * (and also in CD8") T cells frequently fall into one of two phenotypes, Thl and Th2, in both murine and human systems (Romagnani. 1991, Immunol Today 12: 256-257, Mosmann. 1989, A nu Rev Immunol. 7: 145- 173). Thl cells produce interleukin 2 (IL-2), tumor necrosis factor (TNFα) and interferon gamma (IFNγ) and they are responsible primarily for cell-mediated immunity such as delayed type 1 Siypersensitivity. Th2 cells produce interleukins, IL-4, IL-5, IL-6, IL-9, IL-10 and IL-13 and are primarily involved in providing optimal help for humoral immune responses such as IgE and IgG4 antibody isotype switching (Mosmann, 1989. Annu Rev Immunol. 7: 145-173). Strongly polarized Thl and Th2 responses not only play different roles in protection, they can promote different immunopathological reactions. Thl -type responses are involved organ 23pecifιc autoimmunity such as experimental autoimmune uveoretinitis (Dubey et al. 1991 , Eur Cytokine Network 2 : 147-152), experimental autoimmune encephalitis (EAE) (Beraud et al. 1991. Cell Immunol 133 : 379-389) and insulin dependent diabetes mellitus (Hahn et al 1987, Eur J Immunol 18 : 2037-2042), in contact dermatitis (Kapsenberg et al, Immunol Today 12 : 392-395), and in some chronic inflammatory disorders. In contrast Th2-type responses are 25esponsible for triggering allergic atopic disorders (against common environmental allergens) such as allergic asthma (Walker et al, 1992. Am Rev Resp Dis 148 : 109-115) and atopic dermatitis (van der Heijden et al, 1991. J Invest Derm 91 : 389-394), are thought to exacerbate infection with tissue-dwelling protozoa such as helminths (Finkelman et al, 1991 , Immunoparasitol Today 12 : A62-66) and Leishmania major (Caceres-Dittmar et al. 1993. Clin ZQExp Immunol 91: 500-505). are preferentially induced in certain primary immunodeficiencies such as hyper-IgE syndrome (Del Prete et al. 1989, J Clin Invest 84: 1830-1835) and OmennOs syndrome (Schandene et al. 1993. Eur J Immunol 23: 56-60). and are associated with reduced hyper-IgE syndrome (Del Prete et al, 1989, J Clin Invest 84: 1830-1835) and OmennOs syndrome (Schandene et al, 1993, Eur J Immunol 23: 56-60), and are associated with reduced ability to suppress HIV replication (Barker et al. 1995. Proc Soc Nat Acad Sci USA 92: 1 1 135-1 1 139). Thus, it is clear that modulation of the lymphokine profiles of the aforementioned disease states would be of therapeutic benefit. Promoting a Thl response would most likely lead to the reversal of a Th2 phenotype and vice versa. Monoclonal antibodies (mAb) to lymphokines. lymphokines themselves and other agents such as thiol antioxidants (Jeannin et al. 1995. J Exp Med 182: 1785 - 1792) have been shown to reverse the pathogenesis of certain diseases by inhibiting the disease-promoting cytokine pattern, either Thl or Th2. For example, intracellular protozoan infections are limited by IFNγ but exacerbated by IL- 4. while nematode infections are controlled by IL-4 and exacerbated by IFNγ (Heinzel et al. 1989. J Exp Med 162: 59-72, Else et al. 1994, J Exp Med 179: 347-351). Insulin- dependent diabetes mellitus in NOD mice and EAE in mice and rats can be ameliorated by treatment with IL-4 or anti- IFNγ mAb before development of the disease (Rapoport et al, 1993. JExp Med 178: 87-99. Racke et al, 1994, J Exp Med 180: 1961-1966, Campbell et al, 1991. J Clin Invest 87: 739-742). In addition, autoimmune graft versus host disease (GVHD) that is characterized by a systemic lupus erythrematosus-like syndrome is associated with Th2 lymphokine production and is inhibited by anti-IL-4 antibody (Umland et al. 1992. Clin Immunol Immunopathol 63: 66-73). On the other hand, Thl cytokines are produced in acute GVHD. in which donor CD8 + T cells develop into CTL and destroy the host immune system. Treatment with anti-IFNγ or anti-TNFα mAb ameliorates disease, and treatment with anti-IL-2 mAb converts acute GVHD to autoimmune GVHD (Via and Finkelman. 1993, Int Immunol 5: 565-572). Clinical trials of native and recombinant IL-2 in treating HIV-infected patients have been in progress since 1983 (Volberding et al. 1987, AIDS Res Hum Retroviruses, 3: 1 15-124). Here, the relationship comes from the fact that development of AIDS has been reported to be associated with a shift in the pattern of lymphokines produced (Clerici and Shearer, 1994. Immunol Today 15: 575-581). Over time, in an infected individual progressing towards disease, a decreased expression of Thl lymphokines such as IL-2 occurs (Maggi et al, 1987, Eur J Immunol 17: 1685-1690, Gruters et al, 1990, Eur J Immunol 20: 1039-1044. Clerici et al. 1993, J C/ Invest 91: 759-765), concomitant with an increased production of Th2 lymphokines such as IL-4 and IL-10 (Clerici et al, 1994. J Clin Invest 93: 768-775, Hoffman et al, 1985, Virology Ul: 326-335). T-cells from asymptomatic or long term survivors treated with IL-2 enhanced their anti-HIV activity whereas exposure to IL-4 or IL- 10 reduced their ability to suppress HIV replication and to produce IL-2 (Barker et al. 1995. Proc Soc Nat Acad Sci USA 92: 1 1 135-1 1 139). These current immunomodulatory therapeutics (mAbs and recombinant cytokines) are, however, not without limitations. For example with chronic monoclonal antibody treatment, the host animal develops antibodies against the monoclonal antibodies thereby limiting their usefulness. 'Humanized' monoclonal antibodies have been developed which apparently reduces the risk of an induced immune response to these mAbs. However, these are still under development, and in addition these new mAbs remain large proteins and therefore may have difficulty reaching there target sites. Cytokine-based therapeutics also have limitations. For example, IL-12 treatment of autoimmune GVHD leads to the development of acute GVHD in mice. Ribavirin® (l -b-D-ribofuranosyl-l,2,4-triazole-3-carboxamide) is a synthetic nucleoside capable of inhibiting RNA and DNA virus replication (Huffman et al. 1973, Antimicrob. Agents Chemother 3: 235. Sidwell et al, 1972, Science 177: 705). We have confirmed the observations of others who suggested that Ribavirin®. in addition to its antiviral activity, has an effect on certain immune responses (reviewed Jolley and Suchil, 1984, Clinical Applications of Ribavirin®: p93-96). We have also confirmed observations of others that Ribavirin® affects the proliferation of mitogen- and antigen-activated T and B lymphocytes. (Tarn et al, 1995 (data not shown), Peavy et al, 1980, Infection and Immunity 29: 583-589) and then when combined with cyclosporin. Ribavirin® showed efficacy in long term allograft survival . Jolley et al (1988. Transplantation Proc 20: 703- 706). In addition, we have significantly advanced the prior research by demonstrating that Ribavirin® modulates the cytokine pattern of an immune response at least in part by promoting a Thl response and suppressing a Th2 response. In hindsight, this discovery is not inconsistent with prior research. First. Ribavirin® is known to inhibit both functional humoral immune responses, (Peavy et al, 1981, J Immunol 126: 861-864, Powers et al, 1982. Antimicrob Agents Chemother 22: 108-114) and IgE-mediated modulation of mast cell secretion (Marquardt et al. 198 ', J Pharmacol Exp Therapeutics 240: 145-149, (both Th2 lymphokine-mediated events). Second, Ribavirin® antagonizes the antiviral effect of azidothymidine (AZT) in peripheral blood lymphocytes from HIV patients (Vogt et al. 1987. Science 235: 1376-1379). This finding is significant because AZT decreases IL-2 receptor (IL-2R) but not IL-2 expression (Viora and Camponeschi, 1995, Cell Immunol 163: 289-295). It is therefore possible that Ribavirin® antagonizes AZT by modulating IL- 2 expression and elevating depressed levels of IL-2R. Third, Ribavirin® treatment of an immuno-compromised patient for chronic GVHD (a Th2-mediated disorder) led to a dramatic resolution of the disease, an outcome which did not occur with conventional immunosuppressive therapies such as cyclosporin and glucocorticoids (Cassano, 1991, Bone Marrow Transplantation 1: 247-248). Finally, Ribavirin® treatment (one year) of patients for hepatitis C (HCV) revealed fewer lymphocyte aggregates and far less liver damage than placebo controls (Dusheiko et al, 1994. Hepatology 20: 206A). This observation may reflect the fact that although, the predominant immune response to hepatitis C is mediated by Thl lymphokines, T cells of the Th0/Th2 phenotype can be infected by HCV (Zignego et al, 1994, unpublished data) and this infection may drive further antibody-mediated destruction of hepatocytes. BRIEF DESCRIPTION OF THE DRAWINGS TABLE 1 represents the resting and PMA/ionomycin-activated levels, at 48 and 72h, of the lymphokines, IL-2, IL-4. TNFα and IFNγ (pg/ml) measured in extracellular supernatants and the cell surface expression of IL-2 (IL-2R) and IL-4 (IL-4R) receptors (mean channel fluorescence intensity) from human T cells. FIGURE 1 is a graphical representation of the effect of Ribavirin® and interferon alpha on the extracellular expression of IL-2, IL-4. TNFα and IFNγ in PMA/ionomycin- activated T lymphocytes. Results are expressed as percentage of the increased lymphokine expression following PMA/ionomycin treatment alone. FIGURE 2 is a graphical representation of the effect of 2, 10 or 50 mM Ribavirin® in the presence of 2000 U/ml interferon alpha (left panels) and the effect of 500. 1000 or 2000 U/ml interferon alpha (right panels)in the presence of 10 mM Ribavirin® on the extracellular expression of IL-2 (A and C) and IL-4 (B and D) in PMA/ionomycin- activated T lymphocytes. FIGURE 3 is a graphical representation of the effect of Ribavirin® and interferon alpha on IL-2. IL-4 and IFNγ mRNA expression in PMA/ionomycin-activated T lymphocytes. FIGURE 4 is a graphical representation of the effect of Ribavirin® and interferon alpha on the cell surface expression of IL-2 and IL-4 receptors in PMA ionomycin- activated T lymphocytes. Results are expressed as percentage of the increased lymphokine receptor expression following PMA/ionqmycin treatment alone. FIGURE 5 is a graphical representation of the expression of intracellular IL-2 expression in resting (A and E) or activated CD4 T (top panel) or CD8 + (bottom panel) T cells treated with PMA/ionomycin alone (B and F) or in the presence of 10 mM Ribavirin® (C and G) or 5000 U/ml interferon alpha (D and H). Data from one experiment is shown and represented as the percentage of cells showing double positive staining for IL-2 and CD4 or CD8. FIGURE 6 is a graphical representation of contemplated Ribavirin® analogs. FIGURE 7 is a collection of graphs showing the results of various concentrations of Ribavirin® analogs on IL-2, TNF-α, IFN-γ, IL-4 and IL-5. SUMMARY OF THE INVENTION In accordance with one aspect of the present invention, the nucleoside, Ribavirin®®. is administered to a patient in a dosage range which is effective to modulate lymphokine expression in activated T cells. In particular, Ribavirin®® is used to suppress Th2-mediated T cell responses and promote Thl -mediated T cell response. Thus, instead of administering Ribavirin®® in its well-recognized role as an anti- viral agent. Ribavirin® is herein used in the treatment of imbalances in lymphokine expression. Such imbalances may be found to be concomitants of allergic atopic disorders such as allergic asthma and atopic dermatitis, helminth infection and leishmaniasis, and various primary and secondary immunodeficiencies, which may or may not also be associated with viral infection. In accordance with other aspects of the present invention, one or more Ribavirin® analog is administered to a patient in a dosage range which is effective to modulate lymphokine expression in activated T cells. The Ribavirin® analog(s) may be used to suppress or enhance Thl or Th2 -mediated T cell responses. DETAILED DESCRIPTION OF SPECIFIC EMBODIMENTS In a preferred embodiment, Ribavirin® is administered orally to a human patient in a dosage which achieves a blood serum level averaging 0.25 - 12.5 mg/ml, and most preferably, approximately 2.5 mg/ml. In a typical individuals, this optimum serum level, works out to be approximately 4.5 mg/kg/day of body weight which can be administered in doses from 200 - 1200 mg. Preferably the dosages are divided into a number of smaller doses which are then administered throughout the day. Since Ribavirin® has been on the market for several years, many dosage forms and routes of administration are known, and all appropriate dosage forms and routes of administration may be utilized. For example, in addition to oral administration, Ribavirin® may given intravenously, intramuscularly, intraperitoneally, topically, and the like, all of which are known. Pharmaceutical formulations comprising Ribavirin® may also comprise one or more pharmaceutically acceptable carrier, which may include excipients such as stabilizers (to promote long term storage), emulsifiers. binding agents, thickening agents, salts, preservatives, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absoφtion delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the Ribavirin®. its use in the therapeutic compositions and preparations is contemplated. Supplementary active ingredients can also be incorporated into the compositions and preparations. In addition to the therapeutic uses of the Ribavirin® contemplated herein, Ribavirin® may also be used as a laboratory tool for the study of absoφtion, distribution, cellular uptake, and efficacy. It has also been discovered that several Virazole analogs (previously known and unknown) which had earlier been rejected as having minimal activity also have significant cytokine activity. Our research shows that there are several classes of Virazole analogs having such activity, and examples are given below under the heading "Ribavirin® Analogs." These examples are intended to characterize positions at which Virazole can be modified to achieve active compositions, and this disclosure should therefore not be limited to the specific modifications shown. It is further contemplated that these modifications can be applied to the standard D form of Virazole, as well as to the L form of Virazole. EXAMPLES Cell Lines And T Cell Purification Peripheral blood mononuclear cells (PBMCs) were isolated from the buffy coat following Ficoll-Hypaque density gradient centrifugation of 60 ml blood from healthy donors. T-cells were then purified from the PBMCs using Lymphokwik lymphocyte isolation reagent specific for T-cells (LK-25T, One Lambda, Canoga Park CA). An average yield of 40 - 60 x 10^ T-cells were then incubated overnight at 37 °C in 20 - 30 ml RPMI-AP5 (RPMI-1640 medium (ICN, Costa Mesa, CA) containing 20 mM HEPES buffer. pH 7.4. 5 % autologous plasma, 1 % L-glutamine, 1 % penicillin/streptomycin and 0.05 % 2-mercaptoethanol) to remove any contaminating adherent cells. In all experiments, T-cells were washed with RPMI-AP5 and then plated on 96-well microtitre plates at a cell concentration of 1 x 10^ cells/ml. T-Cell Activation And Ribavirin® Treatment T-cells were activated by the addition of 500 ng ionomycin and 10 ng phorbol 12- myristate 13-acetate (PMA) (Calbiochem, La Jolla. CA) and incubated for 48 - 72h at 37 °C. PMA/ionomycin-activated T-cells were treated with 0.5 - 50 mM Ribavirin® or with 250 - 10000 U/ml of a control antiviral, interferon-alpha (Accurate, Westbury, NY) immediately following activation and re-treated 24 h later. T-cells from each plate were used for immunofluorescence analysis and the supernatants used for extracellular cytokine measurements. Following activation, 900 ml cell supernatant from each microplate was transferred to another microplate for analysis of cell-derived cytokine production. The cells are then used in immunofluorescence analyses for intracellular cytokine levels and cytokine receptor expression. Extracellular Cytokine Analyses Cell-derived human cytokine concentrations were determined in cell supernatants from each microplate. Activation-induced changes in interleukin-2 (IL-2) levels were determined using a commercially available ELISA kit (R & D systems Quantikine kit, Minneapolis. MN) or by bioassay using the IL-2-dependent cell line, CTLL-2 (ATCC, Rockville. MD). Activation -induced changes in interleukin-4 (IL-4), tumor necrosis factor (TNFα) interieukin-8 (IL-8) (R & D systems (Quantikine kit, Minneapolis, MN) and interferon- gamma (IFNγ) (Endogen (Cambridge, MA) levels were determined using ELISA kits. All ELISA results were expressed as pg/ml and the CTLL-2 bioassay as counts per minute representing the IL-2-dependent cellular incoφoration of ^H-thymidine (ICN, Costa Mesa, CA) by CTLL-2 cells. Direct Immunofluorescence Studies (Cytokine Receptors) For direct staining with fluorescence-conjugated antibodies to cell surface antigens, the cells were washed twice with isotonic saline solution, pH 7.4 (Becton Dickinson, Mansfield. MA) and re-suspended in 50 ml isotonic saline solution and split into two samples. One sample aliquot was co-stained with either PE-anti CD25/FITC-anti CD4 or PE-rat anti mouse IgG + anti-CD wl24/FITC-anti CD4 mAb and non-specific fluorescence was assessed by staining the second aliquot with PE/FITC-labeled isotype-matched control monoclonal antibody. All fluorescence-labeled monoclonal antibodies were obtained from Becton Dickinson (San Jose, CA) except for anti-CDwl24 which was obtained from Pharmingen, San Diego, CA. Incubations were performed at 4 °C in the dark for 45 min using saturating mAb concentrations. Unincoφorated label was removed by washing in PBS prior to the analysis with a FACScan flow cytometer (Becton Dickinson). Antigen density was indirectly determined in gated live CD4 * T cells and expressed as the mean channel of fluorescence (MCF). Surface expression of specific antigen (CDwl24. CD25) was represented as the mean channel shift (MCS) obtained by subtracting the MCF of FITC- or PE-labeled isotype-matched (IgGl) control mAb-stained cells from the MCF of FITC- or PE-labeled antigen-specific mAb stained cells. Alternatively, surface expression of the CD4 + -subset of cells stained with CD28 mAb was determined by subtracting the MCF of CD28+ CD4+ from the MCF of CD28" CD4" cells. The viability of control untreated and Ribavirin® and interferon a-treated cells were determined in each batch of all oligonucleotides in multiple donors by staining with the vital dye, propidium iodide (5 mg/ml final concentration). The percentage of live cells which excluded propidium iodide was determined by flow cytometry and was > 90 % (range 90 - 99 %) following treatment with all concentrations used. Immunofluorescence Analyses of Intracellular Cytokine Expression For analyses of the intracellular expression of IL-2 in CD4 + and CD8 + T cell subsets. T cells were first treated for the last 4 h of 48 - 72h activation with 10 mg Brefeldin A (Gibco BRL, Gaithersburg, MD) to minimize secretion of newly synthesized IL-2 into the extracellular milieu. Following activation, 900 ml cell supernatant from each microplate was transferred to another microplate for analysis of cell-derived cytokine production. Prior to direct staining (30 min, 4 C , in the dark) with FITC-conjugated antibodies to the cell surface antigens, CD4 and CD8, the cells were washed twice with isotonic saline solution, pH 7.4 and resuspended in 100 - 150 ml Staining Buffer (phosphate buffered saline, pH 7.4 containing 1% Fetal Calf Serum (FCS) (Hyclone, Logan, UT) and 0.1 % sodium azide), and split into two samples. Stained cells were washed in 1 ml Staining Buffer and cell pellet resuspended in 100 ml Fixation Buffer (4% paraformaldehyde in PBS) following aspiration of the supernatant. Fixed cells were kept at 4 C for 20 mins, then washed in 1 ml Staining Buffer and cell pellet resuspended with mixing in 50 ml Permeabilization Buffer (0.1% saponin (ICN, Costa Mesa, CA) in PBS). Permeabilized cells were stained with PE-labeled IL-2 antibody for 30 min at 4 C in the dark and then washed in 1 ml Permeabilization Buffer, re-suspended in 250 ml Staining Buffer prior to FACS analysis. Analysis of Cytokine mRNA Total RNA was extracted from resting T cells and from Ribavirin® and interferon a- treated and untreated activated T cells using a commercial variation of the guanidium thiocyanate/ phenol extraction technique (Trizol reagent (GIBCO/BRL). RNA was washed with 70% ethanol and finally resuspended in 10 μl DEPC-treated water. cDNA synthesis reaction was performed as per manufacturers instructions (Promega. Madion, WI). Briefly. 1 μg of total RNA was heated at 65° C for 10 min and cooled on ice before combining with 2 μl 1 OX reverse transcription buffer ( 100 mM Tris HCl (pH 8.8), 500 mM KCl, 1% Triton X-100), 5 mM MgCI, 2 μl 10 mM dNTPs (1 mM each dNTP), 0.5 μl RNase inhibitor, 1 μl oligo (dT) 15 primer (0.5 μg/ μg RNA) and 0.65 μl AMV reverse transcriptase (H. C). The reaction was incubated at 42°C for 1 h followed by at 95°C for 10 min and 5 min on ice. The PCR reaction was performed using GeneAmp PCR kit (Perkin-Elmer Cetus, Foster City, CA). In a fresh tube, RT reaction mixture (3 μl) was combined with 5 μl 10 X PCR buffer ( 500 mM KCl, 100 mM Tris-HCl, pH 8.3, 15 mM MgCl 2 and 0.01 % (w/v) gelatin), 1 μl 10 mM dNTPs and 1 U of Taq DNA polymerase. The primers used were as follows: interleukin-2. interleukin-4. interferon-g (human) primers (Stratagene, La Jolla. CA) and pHE7 ribosomal gene. Amplification conditions were 45 sec at 94°C, 1 min at 57 ϋ C and 2 min at 72°C for 35 cycles, followed by 8 min at 72°C. PCR products were analyzed on 2% agarose gel containing ethidium bromide. Following electrophoresis, PCR products were transferred to Hybond N+ membrane (Amersham, Arlington Heights, IL) in 20 X SSC overnight and immobilized using 0.4 M NaOH. Blots were hybridized with 2 P- γATP labeled oligonucleotide probes in Rapid - hyb buffer (Amersham) for 1 h at 42° C. Each cytokine primer mix was used as a radiolabeled probe (as per instructions). Equivalent loading was assessed following hybridization with a probe generated from pHE7 sense primer. Washed blots were then analyzed using Phosphorlmager. Effect of Ribavirin® on Extracellular Cytokine Levels in Activated T Cells PMA/ionomycin treatment (48 - 72h) of human T-cells substantially increased the levels of all the cytokines analyzed i.e. IL-2, IL-4, TNFα, IFNγ (TABLE 2). The first number in each cell depicts the arithmetic mean, and the numbers in parenthesis depicts the relevant ranges. N = 4. In a representative experiment shown in Figure 1 , addition of Ribavirin®. in the dose range 0.5 - 50 mM, augmented activated levels of the Thl cytokines, IL-2 and TNFα maximally at 5 mM (30%) and 20 mM (36%) respectively. In contrast, interferon-a, inhibited IL-2 and TNFα expression in a dose-dependent manner (range 250 - 10000 U/ml, maximal inhibition 33 and 38% respectively), when compared to levels in untreated activated T cells. In addition, Ribavirin® mediated a concomitant decrease in activated levels of the Th2 cytokine, IL-4 (peak inhibition of 74% at 2 mM) whereas interferon-a maximally increased extracellular IL-4 by 26% (10000 U/ml). Using combinations of Ribavirin® and interferon alpha, Figure 2 shows that a constant 2000 U/ml of interferon alpha suppressed the Ribavirin® dose-dependent augmentation of activated IL-2 levels (A) and reversed the inhibition of activated IL-4 levels (C). Similarly. a constant 10 mM of Ribavirin® reversed the interferon alpha-mediated dose-dependent inhibition of activated IL-2 levels (B) and suppressed the augmentation of activated IL-4 levels (D). Effect of Ribavirin® on Cytokine mRNA Levels in Activated T Cells These opposing effects of Ribavirin® and interferon-a on activated extracellular cytokine levels were also observed at the level of transcription. Figure 3 shows that PMA ionomycin treatment of human T-cells substantially augments IL-2, IL-4 and IFNγ mRNA levels. Treatment with Ribavirin® (2, 5 and 10 mM) following T cell activation. elevates IL-2. decreases IL-4 and has no effect on IFNγ mRNA. In contrast, interferon a. at 1000. 2000 and 5000 U/ml decreases IL-2, increases IL-4 and decreases IFNγ mRNA. Therefore the respective dose-dependent effects of Ribavirin® and interferon a on IL-2, TNFα. and IL-4 mRNA expression paralleled the ELISA analyses. These data suggest that Ribavirin® promotes the synthesis of the Thl cytokines, IL-2 and TNFα and inhibits the expression of the Th2 cytokine, IL-4 in activated human T cells Effect of Ribavirin® on IL-2 and IL-4 Receptor Levels in Activated T Cells Using FACS analysis, we compared the effects of Ribavirin® and interferon a on expression of IL-2 (CD25) and IL-4 (CDwl24) receptor expression in activated T cells. PMA/ionomycin-treatment increases CD25 and CDwl24 expression from resting levels of 50.16 ± 0.45 and 62.31 ± 1.46 to activated levels of 162.48 ± 2.89 and 87.53 ± 3.98 respectively (n = 4). In a representative of 3 experiments, Figure 4 show that Ribavirin® (1 - 50 mM) has little effect on activated levels of IL-2 and IL-4 receptor whereas interferon a, in the dose range 250 - 10000 U/ml, decreased IL-2 receptor and increased IL-4 receptor expression in a dose-dependent manner, when compared to receptor levels in control activated T cells. Therefore, these data show that the effect of Ribavirin® on cytokine synthesis acts independently of cytokine receptor expression. In contrast, the effect of interferon a treatment on IL-2 and IL-4 receptor correlates with that observed with its effect on activated IL-2 and IL-4 expression. Effect of Ribavirin® on Intracellular IL-2 Levels in CD4 and CD8+ Subsets of Activated T Cells We examined whether the effect of Ribavirin® on IL-2 expression was specific to CD4 " or CD8" T cells. Intracellular IL-2 expression in fixed and Permeabilized activated T cells was determined by two-color flow cytometry using fluorescence-labeled antibodies to CD4 or CD8 and to IL-2. Figure 5 shows that following treatment with Ribavirin® at 10 mM. the percentage of CD4" T cells expressing IL-2 rose from 82 to 91% and the percentage of CD8 + expressing IL-2 increased from 81 to 91%. In contrast, the percentage of IL-2-expressing CD4 + and CD8 ^ cells following interferon-a-treatment (5000 U/ml) was 81 and 71% respectively. These data suggest Ribavirin® has an effect on intracellular IL-2 expression which does not discriminate between CD4" or CD8 * T cell subsets. In contrast, interferon-a-treatment has little effect on CD4" T cells and even reduces IL-2 expression in the CD8 * T cell subset. Ribavirin® Analogs There are several classes of Ribavirin® analogs which are contemplated to be clinically effective in modulating Thl or Th 2 -mediated T cell responses. This includes molecules falling with the generic formulae of Figure 6, wherein X is O, S, CH 2 , CHOH or N-CO-R,,; A, B and C are independently N, P, CH, C-OH, C-CH 3 , C-alkyl, C-alkenyl, C- CH,,-CN, C-halogen. C-CN, C-COOCH 3 , C-NH,, C-SNH,, C-SO,-NH 2 , C-CONH 2 , C-CS- NH 3 , C-C(NH)NH,, CPO,-NH 2 , or C-heterocyclic ring system; D is S, Se, Te, PH, NH or NR,,; R, is H. (CH 2 )p(OH), halogen, CN, (CH,)pONH 2 , (CH 2 )pNH 2 , CH 3 , CH,S >H or (CH,)-heterocyclic ring; R 2 is H. OH, OCH 3 , SH, SCH 3 , halogen, CN, NH 2 , ONH 2 , NHCHj, (CH,)OH. (CH,)pNH 2 , CH 3 , or COOMe; R 3 R 4 , R,, R«, R 7 and R g are independently H. OH. OCH 3 , SH. SCH 3 , halogen, CN, NH,, ONH,. NHCH 3 , (CH,)OH, (CH,)pNH,, CH 3 , COOMe or phenyl; R, is H, halogen, NH 2 , CH 3 , CONH, CSNH,, COOMe, SNH,, SO,NH,, PO,NH,, (CH 2 )p, (CH 2 )p-heterocyclic ring system or (CH 2 )p- glucose; R 10 is H, halogen, NH 2 , CH 3 , CONH, CSNH 2 , COOMe, SNH 2 , SO,NH 2 , PO 2 NH,, (CH,)p, (CH,)p-heterocyclic ring system, (CH 2 )p-glucose, O-CH 3 , O-CH 2 CH 3 or amino acid: Y is O, S, NH»HC1, NOH, NOCH 3 or NOCH 2 PH; R 10 & Y in combination are a heterocyclic ring systems such as thiazole, imidazole. etc., R,, is CH 3 (CH 2 )pNH 2 , (CH,)p- heterocycle. (CH 2 )p-amino acid or (CH,)p-sugar (glucose etc); p is an integer between 0 and 8; and the above includes both L and D nucleosides. Such molecules can be manufactured according to one or more of the following exemplary schemes. 1. Synthesis of 1 CN 1369 (Pyrazomycin): The synthetic methodology for this compound is described in the following references: (a) J. Farkas, Z Flegelova and F. Sorm, Tetrahedron Letts.,22, 2279(1972); (b) S. De Bernardo and M. Weigele, J. Org. Chem., 41, 287 (1976); (c) J. G. Buchanan, A. Stobie and R. H. Wightrnan, J. Chem. Soc. Chem. Commun.. 916 (1980); N. Karagiri, K. Takashima, T. Haneda and T. Kato, J. Chem. Soc. Perkin Trans.!, 555 (1984). 2. Synthesis of 1CN3438 (1-β-D-xylofuranosyl-l ,2.4-triazole-3- carboxamide): The synthesis of this compound was accomplished by following the reported procedure described in J. T. Witkowski, M. Fuertes, P. D. Cook and R. K. Robins. J. Carbohydr. Nucleosides, Nucleotides 2(1), 1 (1975)). 3. Synthesis of 1CN3844 (1 (5-O-sulfamoyl-β-D-ribofuranosyl)-l ,2,4- triazole-3-carboxamide): The compound was prepared by following the procedure disclosed in G. D. Kini, B. M. Henry, R. K. Robins, S. B. Larson, J. J. Marr, R. L. Berens, C. J. Bacchi, H. C. Nathan and 3.S. Keithly, J. Med. Chem., 33, 44 (1990). 4. Synthesis of 1CN4625 (1 (3-deoxy-β-D-erythropentofuranosyl)-l ,2,4- triazole-3-carboxamide): The compound was prepared by utilizing the following synthetic method. 5. Synthesis of ICN5531 (5-amino- l-β-D-ribofuranosylpyrazol-4- carboxamide): The synthetic methodology reported in B. K. Bhattacharya, R. K. Robins and G. R. Revankar. J. Heterocyclic Chem., 21, 795 (1990) was followed to prepare the titled compound. 6. Synthesis of 1 CN5676 (l-β-D-arabinofuranosyl-l,2.4-triazole-3- carboxamide): The synthesis of this compound was accomplished by following the reported procedure in J. T. Witkowski, M Fuefles, P. D. Cook and R. K. Robins. J. Carbohydr. Nucleosides, Nucleotides. 2(1 ), 1 (1975)). 7. Synthesis of ICN5839 (l-β-D-erythrofuranosyl-l,2,4-3-carboxamide): This compound was prepared using the synd etic sequence described below: 8. Synthesis of ICN6242 (2-bromo- 1 -β-D-ribofuranosylimidazole-4- carboxamide): 1 CN6242 was prepared by following the method shown below. ef;P. C. Srivastava, 0. A. Ivanovics, R. J. Rousseau and R. K. Robins, J. Org. Chem., 40, 2920 (1975) 9. Synthesis of ICN11808 (l-β-D-ribofiιrauosyl-pyιazo]e-3,4-dicaιboxamide). The synthesis of this compound was described in Y. S. Sanghvi, B. K. Bhattacharya, G. D. Kini, S. S. Matsumoto, S. B. Larson, W. J. Jolley, R. K. Robins and G. R. Revankar, J. Med. Chem., 33, 336 (1990) and was prepared accordingly. 10. Synthesis of 1CN 12204 (2-(β-D-ribofiύranosyI)nnidazole-5-carboxaιιnde): The synthesis of this compound was achieved by following the reported procedure ii' J. Igoleo, T. H. Dinh, A. Keib and C. Perreur, Chimie Therapeuticμie, 207 (1972). For the Carbocylic 4'-thiosugar and 4'-azasugar derivatives of the Ribavirin® analogs, the following sugars could be condensed with appropriate het&ocyclic compounds and derivatized as described in the above schemes and references. 4'-Thiosugar Carbocyclicβugar 4'<Aza8ugar 1. The carbocyclic sugars can be prepared by following the literature procedure reported: M. Yos ikawa, Y. Yoshikawa, Y. Inoue, S. Yamaguchi and N. Murakami, Tetrahedron, 50,9961 (1994); L. Agrofoglio, E. Suhas, A. Parese, R. Condom, S. R. Challand, R. A. Earl and R. Guedj, Tetrahedron, 50, 10611 (1994). 2. The 4-azasugar was prepared by the reported literature procedure: E. J. Reist, D. E. Gueflfroy and L. Goodman, J. Am. Chem. Soc, 87, 677 ( 1965). 3. The 4-thio-D-ribofuranose was prepared by following the literature procedure: M. Hobek and R. L. Whistler in "Methods in Carbohydrate Chemistry," Vol 1,292(1962). Evidence of the effectiveness of the Ribavirin® analogs in modulating THl and Th2 cytokines is set forth in Figure 7 and in the table below. The assays reported here comprise a short list of 35 Ribavirin® analogs tested, and all assays were performed three times. In general, it can be seen that the compounds tested fall into three major categories: (1) compounds such as ICN1369 and ICN3844 which suppressed IFNγ, D -2, EL-4, EL-S and TNFα; (2) compounds such as Ribavirin® which enhanced IL-2 and TNFα and suppressed ILA and D -5; and (3) compounds such as 1CN6242, 1CN3839 and ICN3531 which enhanced EL- 2 and DFNγ and suppressed IL-4 and 1L-5. Such activities Usted above would be potentially beneficial in indications in which modulation of cytokine would impact an appropriate immune response. TABLE 2 Cell concentration per well = 2 x 10" x 24 = 48 x 10" in 48 ml (Total volume of each well = 2000 μl) Cell concentration per well = 2 x IO 6 x 24 = 48 x IO 6 in 48 ml (Total volume of each well = 2000 μl) Thus, Ribavirin® and Ribavirin® analogs have been shown to be effective in modifying lymphokine express in activated T-cells. While specific embodiments and applications have been addressed, it would be apparent to those skilled in the art that many more modifications are possible without departing from the inventive concepts herein. The invention, therefore, is not to be restricted except in the spirit of the appended claims.

Claims: What is claimed is: I. The use of Ribavirin® to modulate lymphokine expression in activated T cells of a human patient. 2. The use of claim 1 wherein Ribavirin® is administered in a dose effective to raise the level of Thl and lower the level of Th2. 3. The use of Ribavirin® to treat a non- viral disease characterized by a cytokine profile in which Thl is reduced below normal and Th2 is increase above normal. 4. The use of claim 3 wherein the disease comprises an allergy. 5. The use of claim 3 wherein the disease comprises an autoimmune disease. 6. The use of claim 3 wherein the disease comprises a helminthic disease. 7. The use of Ribavirin® to treat the non-viral component of a disease having a viral component and a non-viral component, the non-viral component being characterized by reduced Thl levels and increased Th2 levels in activated T-lymphocytes 8. The use of claim 7 wherein the disease involves primary immunodeficiency. 9. The use of claim 7 wherein the disease involves secondary immunodeficiency. 10. The use of claim 7 wherein the viral component involves the human immunodeficiency virus. I I. The use of any of the following compounds in modulating Thl or Th2 expression: where: X is O, S, C , CHOH or N-CO-R,,; A, B and C are independently N, P, CH, C-OH, C-CH„ C-alkyL C-alkenyl, C-CH 2 .- CN, C-halogen, C-CN, C-COOCH 3 , C-NH 2 , C-SNH 2 , C-SO 2 -NH 2 , C-CONH 2 , C-CS-NH 2 , C-C(NH)NH 2 , CPO 2 -NH 2 , or C-heterocychc ring system; D is S, Se, Te, PH, NH or NR 12 ; R, is H, (CH 2 )p(OH), halogen, CN, (CH 2 )pONH 2 , (CH 2 )pNH 2 , CH„ CH 2 SPH or (CH 2 )-heterocyclic ring; R 2 is H, OH, OCHj, SH, SCH 3 , halogen, CN, NH 2 , ONH 2 , NHCH 3 , (CH 2 )OH, (CH 2 )pNH 2 , CH 3 , or COOMe; R 3 R 4 , R„ R 6 , R 7 and R, are independently H, OH, OCH 3 , SH SCH 3 , halogen, CN, NH 2 , ONH 2 , NHCHj, (CH 2 )OH, (CH 2 )pNH 2 , CH 3 , COOMe or phenyl; R, is H, halogen, NH 2 , CH 3 , CONH, CSNH 2 , COOMe, SNH 2 , SO 2 NH 2 , PO 2 NH 2 , (CH 2 )p, (CH 2 )p-heterocychc ring system or (CH 2 )p-glucose; R„ is H, halogen, NH 2 , CH 3 , CONH, CSNH 2 , COOMe, SNH 2 , SO 2 NH 2 , PO 2 NH 2 , (CH 2 )p, (CH 2 )p-heterocychc ring system, (CH 2 )p-glucose, O-CH 3 , O-CH 2 CH 3 or amino acid; Y is O, S, NH-HC1, NOH, NOCH 3 or NOCH 2 PH; R M & Y in combination are a heterocyclic ring systems such as thiazole, imidazole; R n is CH 3 (CH 2 )pNH 2 , (CH 2 )p-heterocycle, (CH 2 )p-amino acid or (CH^-sugar (glucose etc); p is an integer between 0 and 8; and the above includes both L and D nucleosides.

Inventors: AVERETT DEVRON, RAMASAMY KANDSAMY, TAM ROBERT
Applicants: AVERETT DEVRON, ICN PHARMACEUTICALS, RAMASAMY KANDSAMY, TAM ROBERT
Application year: 1997
Main classification: A61K31
IPC codes: A61K31, A61K38, A61K39, A61K45, C07H19